{"id":510193,"date":"2021-07-07T08:03:59","date_gmt":"2021-07-07T12:03:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/"},"modified":"2021-07-07T08:03:59","modified_gmt":"2021-07-07T12:03:59","slug":"replimune-to-present-at-the-william-blair-biotech-focus-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/","title":{"rendered":"Replimune to Present at the William Blair Biotech Focus Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WOBURN, Mass., July  07, 2021  (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u00ae platform, today announced that Robert Coffin, Ph.D., President and Chief Research &amp; Development Officer of Replimune, will participate in a panel titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors\u201d at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.<\/p>\n<p>A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.<\/p>\n<p>\n        <strong>About Replimune <\/strong><br \/>\n        <br \/>Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune\u2019s Immulytic\u00ae platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.\u00a0For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ezzSwK0vF9jrhZMsLatPIYSy7VCfswngkO53JV01S-A3tmbbQd4FnO7_XPbgSLPwpMgOct9Dnaqme92muBZP-A==\" rel=\"nofollow noopener\" target=\"_blank\">www.replimune.com<\/a>.<\/p>\n<p>\n        <strong>Investor Inquiries <\/strong><br \/>\n        <br \/>Chris Brinzey<br \/>Westwicke, an ICR Company<br \/>339.970.2843<br \/>chris.brinzey@westwicke.com<\/p>\n<p>\n        <strong>Media Inquiries<\/strong><br \/>\n        <br \/>Lissette Steele<br \/>Verge Scientific Communications<br \/>202.930.4762 x 409<br \/>lsteele@vergescientific.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/407e86ec-564b-42f5-90ed-e4f2f348899e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u00ae platform, today announced that Robert Coffin, Ph.D., President and Chief Research &amp; Development Officer of Replimune, will participate in a panel titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors\u201d at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Replimune to Present at the William Blair Biotech Focus Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510193","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u00ae platform, today announced that Robert Coffin, Ph.D., President and Chief Research &amp; Development Officer of Replimune, will participate in a panel titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors\u201d at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation &hellip; Continue reading &quot;Replimune to Present at the William Blair Biotech Focus Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T12:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Replimune to Present at the William Blair Biotech Focus Conference 2021\",\"datePublished\":\"2021-07-07T12:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/\",\"name\":\"Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\",\"datePublished\":\"2021-07-07T12:03:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Replimune to Present at the William Blair Biotech Focus Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","og_description":"WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u00ae platform, today announced that Robert Coffin, Ph.D., President and Chief Research &amp; Development Officer of Replimune, will participate in a panel titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors\u201d at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation &hellip; Continue reading \"Replimune to Present at the William Blair Biotech Focus Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T12:03:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Replimune to Present at the William Blair Biotech Focus Conference 2021","datePublished":"2021-07-07T12:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/"},"wordCount":285,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/","name":"Replimune to Present at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=","datePublished":"2021-07-07T12:03:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjEwMiM0Mjg0OTc4IzIxMTA1MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-william-blair-biotech-focus-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Replimune to Present at the William Blair Biotech Focus Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510193"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}